Effects of evolocumab (AMG 145) in hypercholesterolemic, statin-treated, Japanese patients at high cardiovascular risk: Results from the phase III yukawa 2 study
A Kiyosue, N Honarpour, A Xue, S Wasserman… - Journal of the American …, 2015 - jacc.org
Background: Evolocumab (AMG 145), a fully human monoclonal antibody inhibiting PCSK9,
significantly reduced LDL-C in phase 2 and 3 studies. This phase 3 study (the largest …
significantly reduced LDL-C in phase 2 and 3 studies. This phase 3 study (the largest …
[HTML][HTML] A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - The American journal of …, 2016 - Elsevier
Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk–Primary …
A Hirayama, N Honarpour, M Yoshida… - Circulation …, 2014 - jstage.jst.go.jp
Background: YUKAWA is a 12-week, randomized, double-blind, placebocontrolled, phase 2
study evaluating the efficacy and safety of evolocumab (AMG 145) in statin-treated …
study evaluating the efficacy and safety of evolocumab (AMG 145) in statin-treated …
One-year efficacy and safety of evolocumab in Japanese patients―A pooled analysis from the open-label extension OSLER studies―
A Hirayama, S Yamashita, H Inomata… - Circulation …, 2017 - jstage.jst.go.jp
Background: Evolocumab, a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein-cholesterol (LDL-C) levels in Japanese patients by up to …
reduced low-density lipoprotein-cholesterol (LDL-C) levels in Japanese patients by up to …
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects―A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 …
Background: There are concerns that Asian patients respond differently to some
medications. This study evaluated the efficacy and safety of evolocumab among Asian vs …
medications. This study evaluated the efficacy and safety of evolocumab among Asian vs …
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long …
MJ Koren, RP Giugliano, FJ Raal, D Sullivan… - Circulation, 2014 - Am Heart Assoc
Background—Evolocumab (AMG 145), a monoclonal antibody against proprotein
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 …
JG Robinson, BS Nedergaard, WJ Rogers, J Fialkow… - Jama, 2014 - jamanetwork.com
Importance In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9,
reduced LDL-C levels in patients receiving statin therapy. Objective To evaluate the efficacy …
reduced LDL-C levels in patients receiving statin therapy. Objective To evaluate the efficacy …
Design and rationale of the GAUSS‐2 study trial: a double‐blind, ezetimibe‐controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in …
L Cho, M Rocco, D Colquhoun, D Sullivan… - Clinical …, 2014 - Wiley Online Library
Statins effectively lower low‐density lipoprotein cholesterol (LDL‐C), reducing
cardiovascular morbidity and mortality. Most patients tolerate statins well, but approximately …
cardiovascular morbidity and mortality. Most patients tolerate statins well, but approximately …
Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia
MJ Koren, MS Sabatine, RP Giugliano… - Journal of the American …, 2019 - jacc.org
Background: Evolocumab and other anti-PCSK9 antibodies reduced adverse cardiovascular
outcomes in clinical trials of high-risk patients over< 3 years median treatment duration …
outcomes in clinical trials of high-risk patients over< 3 years median treatment duration …
Comparison of LDL-C reduction using different evolocumab doses and intervals: biological insights and treatment implications
SM Wasserman, MS Sabatine… - Journal of …, 2018 - journals.sagepub.com
Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor
evolocumab reduces low-density lipoprotein cholesterol (LDL-C) and the risk of …
evolocumab reduces low-density lipoprotein cholesterol (LDL-C) and the risk of …
相关搜索
- japanese patients effects of evolocumab
- effect of evolocumab statin therapy
- japanese patients monoclonal antibody
- patients with hypercholesterolemia safety of evolocumab
- patients with hypercholesterolemia statin therapy
- monoclonal antibody effects of evolocumab
- elevated risk evolocumab use
- japanese patients pooled analysis
- japanese patients safety of evolocumab
- effect of evolocumab patients with hypercholesterolemia